TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.100nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.100nMAssay Description:Inhibition of Human respiratory syncytial virus A2 Fusion protein expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.160nMAssay Description:Inhibition of RSV Long fusion protein assessed as decrease in virus induced syncytium formation in infected human HeLa/M cellsMore data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.200nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.200nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.200nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.251nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.251nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.251nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.251nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.316nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.316nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.398nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.398nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.501nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.501nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.501nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.501nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.501nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.631nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.660nMAssay Description:Inhibition of Human respiratory syncytial virus A2 Fusion protein expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.794nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 0.800nMAssay Description:Inhibition of RSV long strain fusion protein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by CCK8 ass...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.30nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.30nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.30nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.40nMAssay Description:Inhibition of Human respiratory syncytial virus A2 Fusion protein expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.60nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.60nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.60nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.60nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.60nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.60nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 1.60nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of RSV B fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK8 a...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of Human respiratory syncytial virus A2 Fusion protein expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2.30nMAssay Description:Inhibition of RSV long strain fusion protein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by CCK8 ass...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2.5nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Janssen Pharmaceutical Companies Of Johnson & Johnson
Curated by ChEMBL
Affinity DataEC50: 2.5nMAssay Description:Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microsco...More data for this Ligand-Target Pair